Orthopaedic Industry News & Orthopaedic Company News | Orthogate Professionals

Platelet rich plasma (PRP) market has witnessed appreciable growth due to a growing number of devices being FDA approved in recent years; however the therapeutics market is anticipated to have an uncertain future, even as non-approved therapeutic applications flourish. Although various platelet rich plasma isolation devices have received 510(k) clearance, platelet rich plasma has not been approved for direct injection or implant without prior mixing with the bone graft materials. Following types of plate rich plasma (PRP) preparations are currently available in the market:

• Leukocyte-poor or pure PRP
• Leukocyte PRP
• Pure platelet-rich fibrin clot
• Leukocyte platelet-rich fibrin clot

Free Sample Report@ http://www.sa-brc.com/Global-Platelet-Rich-Plasma-PRP-Market-Assessment–Forecast-2016-2020/up54

In spite of non-regulatory approval, PRP has been widely used in sports medicine.

President Barack Obama’s $1 billion commitment to make American manufacturing more competitive took another step forward Friday when Carnegie Mellon University and the U.S. Department of Defense announced plans for a $253 million robotics research initiative based in Pittsburgh.

The center — funded by 220 government, industry and academic sources — is the latest of 14 manufacturing institutes that are researching technologies like 3-D printing medical implants that will help broken bones heal faster; working on new, streamlined ways of manufacturing lightweight metals; and developing breakthrough fabrics capable of storing energy and monitoring the health of the person who wears them.

Here are four things to know:

1. This patent application covers Aurora's implant family of ZIP ISPs as well as its first polyaxial implant design.

2. The company's new polyaxial interspinous devices offers "full polyaxial maneuverability of the implant components in difficult situations during minimally invasive fusion cases," said Laszlo Garamszegi, Aurora Spine's chief technology officer.

3. This patent represents Aurora Spine's second allowed U.S. patent.

4. The company also has other pending U.S. and international patent applications.

Here are five notes:

1. The FDA cleared the G-Arm B6 Duo, which is a next-generation G-Arm featuring axial tilt and enhanced table access.

2. The surgical imaging technology is intended for orthopedic, spine and neurosurgeons as well as pain physicians.

3. The G-Arm B6 Duo is designed to boost accuracy as well as cut time, infection and radiation.

4. The technology utilizes two X-ray beans asynchronously, offering bilateral video and images.

5. The G-Arm features X-Beam technology and iC-Clear algorithms.